A rapid and sensitive high-performance liquid chromatography (HPLC) method was developed and validated in rat plasma and tissue (heart, liver, kidney and lung) homogenates for the determination of amiodarone and its primary metabolite (desethylamiodarone), using tamoxifen as internal standard. Chromatographic separation was achieved within less than 5 min on a LiChroCART Purospher Star C18 column (55 3 4 mm, 3 mm). The mobile phase, consisting of phosphate buffer (50 mM) with 0.1% formic acid ( pH 3.1) -methanol-acetonitrile (45:5:50, v/v/v), was pumped isocratically at a flow rate of 1.2 mL/min. The detection was conducted at 254 nm for all compounds. Calibration curves were linear (r 2 ! 0.995) in the range of 0.1 -15 mg/mL for amiodarone and desethylamiodarone. The limits of quantification were established at 0.1 mg/mL for both analytes. The overall data of precision and accuracy were in accordance with international guidelines for bioanalytical method validation. Amiodarone and desethylamiodarone were extracted from rat matrices by a liquid-liquid extraction procedure and the mean recovery ranged from 59.9 to 97.6%. This novel HPLC method allows the fast and reliable determination of amiodarone and desethylamiodarone from several rat matrices ( plasma, liver, kidneys, lungs and heart) and was successfully applied in a preliminary pharmacokinetic study.
Introduction
Amiodarone (AM; Figure 1 ), despite the well-known safety concerns ascribed to the drug itself or its major metabolite desethylamiodarone (DEA; Figure 1 ), remains one of the most prescribed and efficacious antiarrhythmic agents (1 -3) . Therefore, in spite of the recent clinical introduction of a new antiarrhythmic drug structurally related to AM-dronedarone-AM is expected to continue as a valuable agent of the limited armamentarium of antiarrhythmic drugs. Indeed, some concerns about the long-term safety of dronedarone still persist (4) .
AM presents some unfavorable and very unusual properties from a pharmacokinetic viewpoint, which determine its pharmacodynamic and toxicological profiles (2, 5) . In humans, AM has shown an erratic gastrointestinal absorption and, consequently, a variable oral bioavailability (20-80%) (2) . Moreover, AM has a huge body tissue distribution and a correspondingly long elimination half-life (6) . Additionally, AM has been recognized as a drug of narrow serum/plasma therapeutic range (0.5 -2.0 mg/mL) (7, 8) and has also been associated with important clinical drug interactions (9) . AM has usually been considered to be the precipitant or interacting agent in the majority of pharmacokinetic-based interactions reported in literature, inducing a change (usually an increase) in serum/plasma levels of co-administered drugs [e.g., digoxin (10) , warfarin (10) , phenytoin (11) , theophylline (10) and simvastatin (12) ]. Nevertheless, contrary to the expectations, few studies have been published describing the interference of other compounds on the pharmacokinetics of AM; specifically, the metabolism of AM was dramatically inhibited by grapefruit juice (13) , the systemic exposure to AM and DEA was significantly reduced by the simultaneous administration with orlistat (14) and, more recently, the exposure of rats to b-naphthoflavone (a polycyclic aromatic hydrocarbon) was found to increase the formation of DEA, probably through cytochrome P450 (CYP) induction (15) . Thus, it is urgent to investigate the potential for relevant drug interactions in which AM is considered the target of interaction (object drug).
Because rat species share many of the pharmacokinetics properties of AM with humans, the rat has been regarded as one of the best models among small laboratory animals for studying pharmaco-toxicological aspects concerning AM; although some metabolic differences exist, it has also been demonstrated that DEA is the principal metabolite of AM in both species (15 -18) . Hence, the availability of a simple, fast and inexpensive bioanalytical method to enable the reliable quantification of AM and its pharmacologically active metabolite DEA in the matrices of rat plasma and tissues is essential to support many non-clinical assays.
Thus far, a few methods have been reported in literature for the simultaneous determination of AM and DEA in rat plasma and tissues; in addition, the published methods require considerably long analysis times (19 -21) and present other limitations such as complex and expensive sample pre-treatment procedures (22) or the use of costly analytical instrumentation [liquid chromatography -mass spectrometry (LC -MS)], which are not available in all laboratories (23) . Thus, a new liquid chromatography assay was herein developed to minimize many limitations of the previous existing methods.
This work describes a high-performance liquid chromatography (HPLC) method that was developed and fully validated for the rapid and simultaneous quantification of AM and DEA from samples of rat plasma and tissues (heart, liver, kidney and lung). Because the method requires small volumes of rat plasma, it is also a valuable tool for application in pharmacokinetic studies with AM in which multiple, serial blood sample collection is desired from individual rats.
Experimental
Chemicals and reagents AM (lot no. 078K1246) was purchased from Sigma-Aldrich (St. Louis, MO) and DEA (lot no. LB33020) was supplied by Sanofi-Aventis (Paris, France). Tamoxifen (TAM; lot no. 035K1270), as citrate salt, was obtained from Sigma-Aldrich and used as internal standard (IS). The chemical structures of these compounds are shown in Figure 1 . Methanol (HPLC gradient grade) and acetonitrile (HPLC gradient grade) were purchased from Merck KGaA (Darmstadt, Germany) and VWR International (Leuven, Belgium), respectively. Ultra-pure water (HPLC grade . 18 MV; homemade) was prepared by means of a Milli-Q water apparatus from Millipore (Milford, MA). All other reagents were of analytical grade: sodium phosphate monobasic purris p.a. (Sigma-Aldrich GmbH; Seelze, Germany), sodium phosphate dibasic anhydrous (Sigma-Aldrich), sodium dihydrogen phosphate dehydrate purum p.a. (Fluka Chemie; Buchs, Switzerland) and formic acid (98-100%) (BDH Chemicals; Poole, England).
Blank rat plasma and tissues Adult male Wistar rats, weighing 300-380 g, were obtained from local animal facilities (Faculty of Health Sciences of the University of Beira Interior). The rats were maintained under controlled environmental conditions (temperature 20 + 28C; relative humidity 55 + 5%; 12-h light/dark cycle). All animals were allowed free access to a standard diet (4RF21, Mucedola, Italy) and water ad libitum before the experimental procedures. Rats not subjected to other pharmacological treatments were previously anesthetized with an intraperitoneal (i.p.) injection of a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg), and then used as the source of the blank plasma and tissue (heart, liver, kidney and lung) samples required for the validation studies. For that, blood samples were collected into heparinized tubes after decapitation of anesthetized rats. The plasma was separated by centrifugation at 4,000 rpm for 10 min (48C) and stored at -208C until use. After exsanguination, liver, kidneys, heart and lungs were quickly removed, weighed and homogenized in distilled water (3 mL of water per gram of tissue); the tissue homogenates were also stored at -208C until use. All animal experimentation was conducted in accordance with the European Directive (2010/63/ EU) (24) for the accommodation and care of laboratory animals and the experimental procedures were approved by the Portuguese Veterinary General Division.
Stock solutions, calibration standards and quality control samples Stock solutions of AM, DEA and TAM (IS) at concentration of 1 mg/mL were individually prepared by dissolving appropriate amounts of each compound in methanol. The stock solutions of AM and DEA were adequately diluted with methanol to give intermediate solutions at 100 mg/mL. Thereafter, stock and intermediate solutions were appropriately used to create six combined spiking solutions at final concentrations of 0.75, 1.5, 3.75, 11.25, 37.5 and 112.5 mg/mL for AM and DEA, which were used to spike aliquots of blank rat plasma (150 mL), and six combined spiking solutions at final concentrations of 2, 4, 10, 30, 100 and 300 mg/mL were used to spike aliquots of blank tissue (heart, liver, kidney and lung) homogenates (400 mL). These procedures allowed the preparation of calibration standards in all considered matrices at six different concentration levels: 0.1, 0.2, 0.5, 1.5, 5 and 15 mg/mL for AM and DEA. The stock solution of IS was daily diluted with watermethanol (60:40, v/v) to obtain a working solution at 50 mg/ mL. All solutions were stored at 48C and protected from light for one month, except the IS working solution, which was prepared on each day of analysis. Quality control (QC) samples were prepared independently in the same biological matrices [rat plasma and tissue (heart, liver, kidney and lung) homogenates].
Apparatus and chromatographic conditions
The chromatographic analysis was performed using a Waters HPLC system (Milford, MA) equipped with an inline solvent degasser (AF), a quaternary pump with controller (model 600), a manual injector (Rheodyne 7725i) and a diode array detector (DAD-2996). All instrumental parts were automatically controlled by Empower software supplied from Waters Corporation.
The chromatographic separation of the two analytes (AM and DEA) and IS was achieved in approximately 5 min, at room temperature, by isocratic elution with a mobile phase of phosphate buffer (50 mM) with 0.1% formic acid ( pH 3.1) -methanol -acetonitrile (45:5:50, v/v/v) pumped at a flow rate of 1.2 mL/min, on a reversed-phase column LiChroCART Purospher Star (C18; 55 Â 4 mm; 3 mm particle size) purchased from Merck KGaA. The mobile phase was filtered through a 0.45 mm filter and degassed ultrasonically for 15 min before use. The injection volume was 20 mL and the wavelength of 254 nm was selected for the detection of all compounds (AM, DEA and IS).
Sample preparation and extraction
The sample pretreatment was previously optimized and the final conditions were as follows. Each aliquot (150 mL) of rat plasma samples was diluted with 150 mL of 0.1M sodium phosphate buffer ( pH 5) and spiked with 20 mL of the IS working solution (50 mg/mL). The mixture was added to 500 mL of n-hexane (used as liquid -liquid extraction solvent), vortexmixed for 30 s and centrifuged at 17,000 rpm for 2 min at 48C. The upper organic layer was transferred to a clean glass tube and the sample was re-extracted twice more with n-hexane (500 mL each time) using the conditions previously described. The whole organic extract was then evaporated to dryness under a nitrogen stream at 608C and the residue was reconstituted in 100 mL of methanol. Following this, an aliquot of the reconstituted extracts (20 mL) was injected into the HPLC system for analysis.
For the extraction from tissues, each aliquot (400 mL) of tissue (heart, liver, kidney and lung) homogenates was spiked with 20 mL of the IS working solution (50 mg/mL); then, the mixture was added to 400 mL of acetonitrile (used as protein precipitating agent), vortex-mixed for 1 min and centrifuged at 17,000 rpm for 10 min at 48C to precipitate the protein content. The supernatant was transferred to a new propylene tube and 1 mL of n-hexane (used as liquid -liquid extraction solvent) was added. The mixture was vortex-mixed for 1 min and centrifuged at 17,000 rpm for 5 min at 48C. The upper organic layer (n-hexane) was transferred to a clean glass tube and the sample was re-extracted twice more with n-hexane (0.8 mL each time) using the same conditions. The organic extract was evaporated to dryness, reconstituted and then injected into the HPLC system using the same procedures as mentioned previously for rat plasma samples.
Method validation
The described method was validated according to the general recommendations published in the last few years concerning bioanalytical method validation and acceptance criteria for validation parameters: selectivity, linearity, sensitivity, precision and accuracy, sample dilution, recovery and stability (25 -27) .
Selectivity was evaluated by comparing the chromatograms generated after the analysis of blank samples ( plasma and heart, liver, kidney and lung homogenates) obtained from six different rats with those achieved from the corresponding spiked samples to investigate the existence of potential chromatographic interferences from endogenous compounds (matrix effects) at the retention times of AM, DEA and IS. Additionally, interferences from drugs (ketamine, xylazine and heparin) usually used in experimental protocols of pharmacokinetic studies were also tested by injecting standard solutions of these compounds.
The linearity of the analytical method was assessed in the range of 0.1 -15 mg/mL for AM and DEA. For that, calibration curves were prepared on five different days (n ¼ 5) using spiked plasma and tissue (heart, liver, kidney and lung) homogenate calibration standards at six different concentration levels. Calibration curves were constructed by plotting the peak-area ratios (analyte/IS) as a function of the respective concentrations. The data were subjected to a weighted linear regression analysis using 1/x 2 as the weighting factor for both analytes (AM and DEA); this weighting factor was selected because it yielded the best fit of peak-area ratios versus concentration (28). The limit of quantification (LOQ) for AM and DEA, defined as the lowest concentration on the calibration curve that can be measured with acceptable intra-day and inter-day precision and accuracy, was assessed respectively by the percentage of coefficient of variation (CV) not exceeding 20% and the percentage of deviation from nominal value (% bias) within +20%. The LOQ was evaluated by analyzing spiked plasma and tissue (heart, liver, kidney and lung) homogenate samples that were prepared in five replicates (n ¼ 5). The limit of detection (LOD) of the analytes (AM and DEA) in plasma and tissue (heart, liver, kidney and lung) homogenates was defined as the concentration that yields a signal-to-noise ratio of 3:1.
Intra-day and inter-day precision and accuracy were assessed by using QC samples analyzed in replicate (n ¼ 5) at three concentration levels (low, medium and high QC samples) representative of the calibration range; the concentrations tested were 0.3, 7.5 and 13.5 mg/mL for AM and DEA. The acceptance criterion for intra-day and inter-day precision (expressed as % CV) was a CV not exceeding 15% (or 20% in the LOQ) and the criterion for accuracy (expressed as percent bias) was a bias value within +15% (or +20% in the LOQ).
The dilution effect (1:4) was also investigated in plasma and tissue (heart, liver, kidney and lung) homogenates with appropriate QC samples at 25 mg/mL for AM and DEA to ensure that samples exceeding the highest concentration (15 mg/mL) of the calibration range could be appropriately diluted with the respective blank matrix, and precisely and accurately quantified. The precision and accuracy of the diluted samples were determined in both intra-day and inter-day assays (n ¼ 5).
The recovery of the analytes (DEA and AM) from plasma and tissue (heart, liver, kidney and lung) homogenate samples, submitted to the previously described pretreatment procedures, was determined using QC samples at three concentration levels (low, medium and high QC samples) and analyzed in replicate (n ¼ 5). The recovery of the analytes was calculated by comparing the analyte peak area of extracted QC samples against equivalent aqueous solutions. The recovery of the IS was also evaluated at the concentration used in the analysis of plasma and tissue homogenate samples.
The stability of AM and DEA was assessed in all matrices ( plasma and tissue homogenates), at low (QC1) and high (QC3) concentration levels, during 4 h at room temperature, 24 h at 48C and 30 days at -20 and -808C to simulate sample handling and storage time in the freezer before analysis (n ¼ 5). Stability of the analytes (AM and DEA) was also studied at 48C within 24 h in the processed samples ( post-preparative stability in methanol) to reproduce the time that samples can spend in the autosampler before analysis. Finally, the stability of AM and DEA was also evaluated after three freeze-thaw cycles at -20 and -808C. Aliquots of spiked samples (QC1 and QC3) were stored at -20 and at -808C for 24 h and thawed unassisted at room temperature, and when completely thawed, the samples were refrozen for 24 h under the same conditions until three cycles were completed. Stability was assessed by comparing the data of QC samples analyzed before (reference samples) and after being exposed to the conditions for stability assessment (stability samples); a stability/reference samples ratio of 85 -115% was accepted as stability criterion (n ¼ 5).
Method application and pharmacokinetic analysis
Following the oral administration of a single dose of AM to Wistar rats (300 -380 g), the analytical method was applied to investigate the plasma pharmacokinetic profiles of AM and its major metabolite (DEA), as well as AM and DEA concentrations present in the tissues (heart, liver, kidney and lung) at the end of the experiments (24 h post-dose). On the day before the pharmacokinetic study, a lateral tail vein of each rat (n ¼ 5) was cannulated under anaesthesia [ketamine (90 mg/kg)/xylazine (10 mg/kg); i.p. injection], by insertion of an Introcan Certo IV indwelling cannula (22G; 0.9 Â 2.5 mm) made of polyurethane (B. Braun Melsungen AG, Melsungen, Germany). The rats fully recovered from anaesthesia and were fasted overnight with free access to water. The next day, rats received 50 mg/kg of AM administered by oral gavage; the solution of AM (12.5 mg/mL) administered to the rats was extemporaneously prepared from a commercial injectable solution of AM (50 mg/ mL), which was appropriately diluted with 5% dextrose solution. After the administration of AM, multiple serial blood samples ( 0.3 mL) were collected into heparinized tubes at prespecified post-dose time points (0.25, 0.5, 1, 2, 4, 6, 8 and 12 h) through the catheter previously introduced in lateral tail vein of the rats. In addition, at 24 h post-dose, under anaesthesia, blood and tissue (heart, liver, kidney and lung) samples were also harvested after decapitation of the rats. The blood and tissue samples were immediately processed as indicated previously. The plasma and tissue homogenates obtained were frozen at -208C until analysis. All animal experiments were conducted in accordance with the European Directive (2010/ 63/EU) (24) for the accommodation and care of laboratory animals and the experimental procedures were approved by the Portuguese Veterinary General Division.
The plasma concentration-time profiles obtained for AM and DEA were submitted to a non-compartmental pharmacokinetic analysis using WinNonlin version 4.1 (Pharsight Co, Mountain View, CA). The peak concentrations of AM and DEA in plasma (C max ) and the time to reach Cmax (t max ) were obtained directly from the experimental data. Other pharmacokinetic parameters were estimated from the plasma concentration data obtained at each time point (0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h): area under the concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the LOQ of the method (AUC 0 -t ), calculated by the linear trapezoidal rule; AUC from time zero to infinite (AUC 0 -1 ), calculated from AUC 0 -t þ (C last /l z ), where C last is the last quantifiable concentration and l z is the apparent terminal elimination rate constant calculated by log-linear regression of the terminal segment of the concentration-time profile; apparent terminal elimination half-life (t 1/2 ) and mean residence time (MRT). The plasma concentrations of AM and DEA lower than the LOQ of the assay were assumed to be zero for all calculations.
Results

Method development
Once identified from the literature the scarcity of bioanalytical methods available for the analysis of AM and its primary metabolite (DEA) in rat plasma and tissues, as well as their major analytical drawbacks, the development of the method herein described was conducted to overcome the current analytical limitations. To achieve satisfactory chromatographic separation associated with short chromatographic running times, a short reversed-phase LiChroCART Purospher Star-C18 column (55 Â 4 mm; 3 mm particle size) was selected. In addition, the outstanding robustness and excellent pH stability indicated by the manufacturer, enabling the development of methods across a wide pH range (1.5 -10.5) were characteristics considered in the column selection. Then, to optimize the best chromatographic conditions to separate the analytes (DEA and AM) in the column, individual and combined solutions of the compounds were directly injected into the HPLC system and several mobile phases were tested using a standard flow rate (1 mL/min); at the beginning, the focus was the chromatographic resolution of AM and DEA. First, the absence of buffer and salt in the mobile phase was considered to reduce the pressure and prolong the column lifetime, avoiding the formation of precipitates due to the limited solubility of salts in organic modifiers. Thus, considering the information available in literature and aiming to minimize the run time while maintaining a good chromatographic resolution between adjacent peaks, different mobile phases were tested consisting of only water and acetonitrile as organic modifier. However, an adequate chromatographic resolution between DEA and AM and peak symmetry was achieved only after changing the aqueous portion of the mobile phase to 50 mM phosphate buffer with a pH value near 3, adjusted with formic acid. After that, the next step was the introduction of an IS (TAM); TAM was the compound selected to be used as IS because it is structurally related to the analytes (AM and DEA) and is commercially available. TAM showed a shorter retention time than the analytes by isocratic elution with a mobile phase of phosphate buffer (50 mM) with 0.1% formic acid ( pH 3.1) -acetonitrile (50:50, v/v), but an overlap of chromatographic peaks of TAM and DEA was observed to an extent that prevented individual peak integration. Trying to reach the complete chromatographic separation of the TAM and DEA, a second organic modifier (methanol in a percentage of 5%) was included in the composition of the mobile phase. A mobile phase composed of phosphate buffer (50 mM) with 0.1% formic acid ( pH 3.1) -methanol-acetonitrile (45:5:50, v/v/v) allowed the complete resolution of the three compounds (TAM, DEA and AM). The flow rate was then set at 1.2 mL/min (isocratic conditions) and all compounds eluted in a short running time of approximately 5 min.
In addition to the optimization of chromatographic conditions for the separation and detection of the IS and analytes (DEA and AM) after the use of standard solutions, the development of an analytical method to quantify drugs or metabolites in biological samples also requires the development of a suitable sample extraction procedure. In fact, sample pretreatment is a vital step in bioanalysis, enabling the removal of proteins that can precipitate on the chromatographic column or eliminate potential matrix interferences. In this case, before selecting a liquid -liquid extraction (LLE) procedure to extract the analytes from rat plasma samples, other simpler and faster sample preparation approaches were tested, particularly the precipitation of proteins with methanol and acetonitrile; however, in these conditions, several peaks of endogenous substances appeared at the retention times of the compounds of interest (lacking selectivity). Afterward, to develop a simple and inexpensive analytical method, LLE procedures using low solvent volumes were considered instead of solid-phase extraction (SPE). Accordingly, several organic solvents (chloroform, dichloromethane, diethyl ether, ethyl acetate and n-hexane) were tested to optimize the selectivity and recovery. The organic solvent that allowed the best selectivity was n-hexane, and a good recovery was obtained by multiple (three) LLE steps using small volumes of solvent. Finally, the LLE procedure established for the preparation of rat plasma samples was selected, as described previously. Because rat tissue (heart, liver, kidney and lung) samples are more complex than those of plasma, this makes the analysis of drugs or metabolites in such biological matrices more difficult and additional steps of sample preparation are usually required. Thus, to determine AM and DEA concentrations in rat tissue samples, tissue homogenization was selected as the first step of tissue sample preparation. As for tissue homogenate samples the application of isolated procedures of protein precipitation or LLE did not provide enough chromatographic selectivity, the subsequent strategy consisted of a protein precipitation step followed by LLE procedures. Acceptable selectivity and recovery were achieved by protein precipitation with acetonitrile followed by LLE with n-hexane using the previously mentioned conditions. Once available, an HPLC system coupled to a diode-array detector (DAD) was used and the maximum absorbance wavelengths of the analytes were investigated, presenting the maximum absorbance at 240 nm for DEA and AM, and at this wavelength the absorption of the IS was also near the maximum. However, to improve the selectivity of the analytical assay against the endogenous interferences of rat matrices, the wavelength selected was 254 nm instead of 240 nm.
Method validation
Selective extraction and chromatographic resolution of the compounds of interest (IS, DEA and AM) from spiked rat plasma and tissue (heart, liver, kidney and lung) homogenate samples were successfully attained using the previously described sample preparation procedures and chromatographic conditions. Typical chromatograms obtained after analysis of the extracts of blank and spiked rat plasma and tissue homogenate samples are shown in Figure 2 . The chromatograms demonstrated that, in all blank rat matrices ( plasma and heart, liver, kidney and lung tissue homogenates), no endogenous compounds interfered at the retention times of the IS and analytes (DEA and AM). In addition, none of the tested drugs (ketamine, xylazine and heparin) frequently used in experimental protocols of pharmacokinetic studies were found to interfere at the retention times of the chromatographic peaks of IS, DEA and AM. Figure 2 . Typical chromatograms of extracted rat samples: blank plasma (A); plasma spiked with DEA and AM at 0.5 mg/mL (B); blank heart tissue homogenate (C); heart tissue homogenate spiked with DEA and AM at 0.5 mg/mL (D). As shown for heart tissue homogenate, similar chromatographic behaviour was obtained for corresponding samples of liver, kidney and lung tissue homogenates.
The linearity of the analytical method in the calibration range of 0.1 -15 mg/mL was demonstrated for both compounds (AM and DEA) in all rat matrices ( plasma, and heart, liver, kidney and lung tissue homogenates; r 2 ! 0.995). The calibration curves were subjected to weighted linear regression analysis and the corresponding parameters are summarized in Table I . Under the experimental conditions described, the LOQ of the assay was set at 0.1 mg/mL for AM and DEA in all rat matrices investigated with acceptable precision and accuracy, as shown in Table II . The LOD of the analytes (AM and DEA) was established at 0.02 mg/mL in plasma and at 0.01 mg/mL in tissue (heart, liver, kidney and lung) homogenates.
The intra-day and inter-day precision and accuracy data of the assay using low, medium and high QC samples for plasma and tissue (heart, liver, kidney and lung) homogenates are shown in Table II . The overall intra-day and inter-day imprecision (% CV) did not exceed 6.56% and the inaccuracy (% bias) was within +7.94%. These data comply with the international guidelines for the validation of bioanalytical methods. Therefore, the method is precise and accurate for the determination of AM and DEA in rat plasma, and heart, liver, kidney and lung homogenate samples. The precision and accuracy were also demonstrated for the sample dilution (1:3) of plasma and tissue (heart, liver, kidney and lung) homogenates (Table II) . These results show that a four-fold dilution with the corresponding blank rat matrices can be appropriately applied if the concentration of the analytes (AM and DEA) in an assayed sample exceeds the highest concentration level of the calibration curve (15 mg/mL).
The recovery values of AM and DEA from rat matrices ( plasma, heart, liver, kidney and lung homogenates) are presented in Table III . The mean recoveries, accounting for AM and its major metabolite (DEA), ranged from 59.9 to 97.6%, and showed low CV values. The recovery of the IS from all rat matrices showed mean values between 72.6 and 91.7%, with CV values not exceeding 4.56%.
From the stability data obtained in rat plasma and tissue (heart, liver, kidney and lung) homogenates, no significant loss was observed for AM and DEA when spiked QC samples (QC1 and QC3) were stored at room temperature for 4 h, at 48C for 24 h, and at -20 and -808C for 30 days. The analytes (AM and DEA) were also demonstrated to be stable after three freeze-thaw cycles at -20 and -808C; in addition, no significant degradation occurred in processed samples (methanol extract) stored at 48C for 24 h. Stability data are summarized in Table IV .
Method application and pharmacokinetic study The HPLC method was successfully applied to the analysis of DEA and AM in serial plasma samples taken over a period of time of 24 h from Wistar rats (n ¼ 5) administered with a single oral dose of AM (50 mg/kg). The blood sample collection performed at 24 h post-dose involved a terminal procedure, and then heart, liver, kidney and lung tissues were excised after exsanguinations, allowing als the application of the method to the determination of AM and DEA concentrations in rat tissue samples. The plasma concentration-time profiles obtained for AM and DEA from each rat are depicted in Figure 3 . Figure 4 shows the corresponding mean plasma concentration-time profiles (n ¼ 5), and the most significant pharmacokinetic parameters of AM and DEA estimated by non-compartmental analysis are summarized in Table V . The concentrations of AM and DEA measured in tissue (heart, liver, kidney and lung) and plasma samples at 24 h post-dose are shown in Table VI .
Discussion
The HPLC method herein described presents important bioanalytical improvements over the few assays previously published for the quantification of AM and DEA in rat plasma and tissue samples (19, 20, 22, 23) , and the method was successfully applied to a preliminary pharmacokinetic study. The analytical method was fully validated in rat plasma and in heart, liver, kidney and lung tissue homogenates, enabling the fast chromatographic analysis of AM and DEA in such biological samples (in approximately 5 min) using simple instrumentation and uncomplicated chromatographic conditions (isocratic elution and detection in UV spectral region); these aspects suggest that the method is appropriate for implementation in almost all laboratories, and fast bioanalytical assays are essential whenever a large number of samples have to be analyzed. At this point, the full validation performed in all rat tissue matrices (heart, liver, kidney and lung) may not be necessary. Indeed, taking into account the general recommendations published in last few years concerning bioanalytical method validation, a partial validation could be acceptable for different matrices within a species (25 -27) . However, for the reliable application of this method to pharmacokinetic assays, the validation parameters selectivity, intra-day precision and accuracy, and stability should be evaluated in all intended biological matrices. Therefore, because the bioanalytical method was under development and implementation for the first time, a full validation was considered to ensure greater confidence in the data. In this method, the plasma sample preparation only involves LLE, and for tissue sample preparation, an additional step of protein precipitation is employed. These procedures are significantly less expensive than those of the method developed by Moor et al. (22) , which combines protein precipitation and SPE for both plasma and tissue samples. Although the method described by Moor et al. (22) appears to be more sensitive for plasma (0.03 mg/mL as LOQ) than the method herein reported (0.1 mg/mL as LOQ), the plasma sample volume used for analysis is higher in the first method (500 mL versus 150 mL). This aspect is important when serial blood sample collection in survival, non-terminal pharmacokinetic studies is required; indeed, a 500 mL plasma sample volume is too large, compromising an experimental design involving serial blood sample collection. Al-Dhawailie (19) reported a method in which an appropriate volume of plasma to perform pharmacokinetic studies (100 mL) was used, but it was validated exclusively for the determination of AM, disregarding the primary pharmacologically and toxicologically active metabolite (DEA), and also presented the disadvantage of a time-consuming chromatographic analysis ( 14 min). Jun and Brocks (20) also developed and validated a method requiring small volumes of rat plasma (100 mL), but exclusively for the determination of AM. This method was improved some years later by Shayengapour and Brocks (21) introducing the metabolite (DEA); however, the primary drawback was not overcome, because long chromatographic analysis times remained ( 14 min). More recently, Shayeganpour et al.
(23) developed another method for AM and DEA in rat plasma and tissues using an LC-MS assay, which required more expensive instrumentation that may not be available in all labs. In addition, in the method developed by Shayengapour et al. (23) , the volume of n-hexane required for LLE was approximately double that used in this method.
As demonstrated in this work, the present method is a useful tool to support rat pharmacokinetic-based studies with AM, making it possible to characterize AM and DEA plasma pharmacokinetic profiles in each rat. As expected, AM has shown an erratic and variable absorption from rat gastrointestinal tract (Figure 3 ). In agreement with Shayeganpour et al. (23) , this preliminary pharmacokinetic study also showed that systemic exposure to DEA (major metabolite) is much lower than exposure to AM, even following oral administration of the parent compound. Bearing in mind that the plasma and tissue (heart, liver, kidney and lung) concentration data measured at 24 h post-dose (Table VI) , it was evident that higher concentrations of AM and DEA were found in tissues than in plasma, supporting their greater plasma-tissue distribution. Additionally, these findings also support the extensive accumulation of AM and DEA in rat lung tissue, which may explain why pulmonary toxicity is one of the most serious toxic effects associated with AM treatment. Indeed, the highest concentrations of AM and DEA were observed in the rat lung and, at this level, the huge DEA concentrations determined in lung tissue (more than 1,000-fold) were comparable to those found in plasma. The results of this pharmacokinetic study corroborate the conclusions of recent non-clinical studies that have also linked the metabolite DEA to pulmonary cytotoxicity induced by AM (15, 29) .
Conclusion
A rapid, sensitive and reliable HPLC method was developed and fully validated for the simultaneous determination of AM and its primary metabolite (DEA) in rat plasma and tissue (liver, kidney, lung and heart) homogenates. In this new HPLC method, the procedures employed for sample preparation and extraction are simple and inexpensive, comprising only LLE for plasma samples and protein precipitation combined with LLE for rat tissue homogenates. The assay was also successfully applied to the quantification of AM and DEA from real samples of plasma and tissues after a single oral administration of AM to Wistar rats. The described method appears to be a useful bioanalytical assay, providing a linear response for both analytes (AM and DEA) in a wide working concentration range, enabling its future application to support several non-clinical pharmacokinetic and/or toxicokinetic-based studies involving the administration of AM to rats; for instance, non-clinical drug -drug or food/herb-drug interaction studies in rat in which AM is regarded as the object drug. 
